Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Peripheral blood stem cells (PBSCs) collected following stimulation with filgrastim are commonly used for autologous hematopoietic transplants. PBSCs are also now being used for some syngeneic and allogeneic hematopoietic transplants involving HLA-matched sibling donors. However, many issues remain unanswered about the use of PBSCs for allogeneic transplants and the effects of filgrastim on healthy individuals. The purpose of this study is to determine the effectiveness of filgrastim stimulated PBSCs in hematopoietic cell transplants involving unrelated donors and to determine the effects of this donation process on unrelated stem cell donors.
| Condition |
|---|
|
Healthy |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors |
| Estimated Enrollment: | 15 |
| Study Start Date: | August 2005 |
| Estimated Study Completion Date: | November 2007 |
This study establishes and evaluates a system to supply peripheral blood stem cell (PBSC)products for use in unrelated donor hematopoietic stem cell (HSC) transplantation. The protocol describes processes for donor identification, education and evaluation. Procedures for administration and monitoring of the stem cell mobilizing agent filgrastim are included. The study also describes procedures for the collection of PBSC products by leukapheresis and includes provisions for indefinite donor follow-up.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
-Healthy adults
Exclusion Criteria:
- Pregnancy or uninterruptible breastfeeding.
- Sensitivity to filgrastim or to E. coli-derived recombinant protein products.
- History of autoimmune disorders, including rheumatic disease and thyroid disorders. Exception: As with bone marrow donations, donors with a history of thyroid disease who have undergone successful therapy may be suitable.
- History of deep vein thrombosis or pulmonary embolism.
- Thrombocytopenia <150 x 10(9)/L (<150,000/uL) at baseline evaluation.
- Current treatment with lithium. Drug interactions between filgrastim and lithium, which may potentiate the release of neutrophils, have not been full evaluated.
- Positive Hemoglobin-Solubility (e.g. SickleDex or equivalent) test.
- Donors receiving experimental therapy or investigational agents.
Contacts and Locations| United States, California | |
| University of California San Francisco Medical Center | |
| San Francisco, California, United States, 94143-0324 | |
| Principal Investigator: | Thomas G. Martin, M.D. | University of California, San Francisco |
| Study Director: | John Miller, M.D.,Ph.D. | National Marrow Donor Program |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00511550 History of Changes |
| Obsolete Identifiers: | NCT00005930 |
| Other Study ID Numbers: | UC-2508 |
| Study First Received: | August 3, 2007 |
| Last Updated: | March 3, 2008 |
| Health Authority: | United States: UCSF Cancer Center Data Safety Monitoring Committee United States: National Marrow Donor Program |
Keywords provided by University of California, San Francisco:
|
peripheral blood stem cells filgrastim-mobilized allogeneic transplantation Unrelated Donors for allogeneic transplantation |
Additional relevant MeSH terms:
|
Lenograstim Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013